Endometriosis is estimated to affect around one in ten women of reproductive age in the UK, yet the journey towards receiving a diagnosis remains extraordinarily long.
In March 2026, Endometriosis UK reported that the average diagnosis time had reached nine years and four months. That represents a deterioration from the eight-year average reported in 2020.
For a condition affecting millions of people globally, nine years is not simply an inconvenient waiting time. It can represent years of pain, repeated appointments, disrupted education, lost productivity, uncertainty around fertility and the exhausting experience of explaining the same symptoms repeatedly to different healthcare professionals.
The technology opportunity therefore begins with a deceptively simple question: why is something experienced over years still so often assessed through disconnected moments?
Endometriosis Is a Longitudinal Condition Living in a Fragmented System
Endometriosis is a chronic condition in which tissue similar to the lining of the womb grows elsewhere in the body. Symptoms can include pelvic pain, painful periods, pain during or after sex, fatigue and difficulties becoming pregnant, although experiences vary considerably between individuals.
Those experiences do not necessarily present themselves neatly during a 15-minute appointment.
Patterns may emerge over months or years. Pain can change across the menstrual cycle. Treatments may help temporarily before becoming less effective. Symptoms can interact with work, sleep, exercise and other aspects of everyday life.
A woman’s history therefore matters.
Yet healthcare information can be fragmented across GP appointments, hospitals, specialists, imaging systems and increasingly consumer health applications.
The patient frequently becomes the integration layer between those systems.
She remembers when the pain started. She explains what happened during previous appointments. She recalls which medication was tried. She describes how symptoms changed and which treatments failed.
After years of doing this, the story itself becomes data.
The question is whether technology can capture that journey more effectively without taking control of it away from the person who lived it.
The Diagnostic Delay Is Getting Worse
The latest figures make the problem particularly difficult to ignore.
Endometriosis UK’s 2026 research found that the average UK diagnosis time has increased to nine years and four months.
Its previous 2024 survey, involving 4,371 people who had received a diagnosis, revealed how complicated those journeys could become.
Almost half of respondents reported visiting their GP at least ten times with symptoms before diagnosis, while 70 per cent had attended five times or more. More than half had visited A&E at least once.
Those numbers suggest that the problem is not simply that women are failing to seek medical help.
Many are repeatedly interacting with healthcare services.
The challenge is recognising the pattern.
Could Technology Help Connect the Dots?
This is where artificial intelligence becomes interesting.
Imagine a woman who has experienced symptoms for three years.
She has symptom records, GP consultations, blood-test results, prescriptions, ultrasound images and perhaps several emergency-department visits.
Individually, none of those pieces of information necessarily provides the answer.
Together, they may create a pattern.
AI systems are particularly good at identifying patterns across large quantities of information. The opportunity is therefore not necessarily to create an algorithm that independently declares that someone has endometriosis.
A more realistic application would help clinicians recognise when a patient’s longitudinal history resembles patterns associated with the condition and indicates that further specialist investigation may be appropriate.
The distinction matters.
AI should not replace the clinician.
It could help ensure that the clinician sees more of the patient’s story.
AI Is Already Entering Endometriosis Imaging
One particularly interesting frontier is ultrasound.
Specialist ultrasound can help identify some forms of endometriosis, but the quality of interpretation depends heavily upon clinical expertise.
That creates a scaling problem.
If only a relatively small number of specialists can consistently recognise difficult cases, increasing access requires either training substantially more specialists or finding ways to distribute some of that expertise.
Artificial intelligence could potentially help.
London-based Endoscan Health, for example, is developing AI tools intended to support specialist ultrasound assessment of endometriosis.
Its current clinical pathway remains clinician-led. Specialist transvaginal ultrasound is performed by qualified practitioners and reviewed by a consultant gynaecologist, while AI assists with reporting. The company is developing image-recognition systems intended to help identify areas potentially affected by endometriosis.
This is precisely the kind of application where AI could become valuable.
The objective is not replacing the specialist.
It is making specialist capability easier to scale.
The Diagnostic Frontier Goes Beyond Imaging
Researchers and companies are also investigating biomarkers, blood tests and other non-surgical diagnostic approaches.
Historically, laparoscopy played a particularly important role in definitively diagnosing endometriosis. Modern clinical guidance increasingly recognises that imaging and clinical assessment can establish diagnoses in many circumstances without requiring surgery purely for diagnostic purposes.
However, there is still no simple equivalent of a pregnancy test that can reliably tell someone whether they have endometriosis.
That leaves an enormous diagnostic opportunity.
Researchers are investigating combinations of biomarkers, microRNAs, immune signatures, imaging and machine learning to determine whether endometriosis can be detected earlier and less invasively.
If somebody eventually develops a cheap, scalable and sufficiently accurate test, its impact could be enormous.
Nine years of uncertainty could potentially become months.
Treatment Innovation Is Changing Too
Diagnosis is only one part of the problem.
Treatment remains another major area of unmet need.
Existing approaches can include pain medication, hormonal treatments and surgery depending on symptoms, circumstances and individual preferences.
These treatments can be effective for some people, but there remains substantial demand for alternatives.
One particularly interesting frontier is non-hormonal treatment.
In March 2026, Swedish biotechnology company Gesynta Pharma began dosing patients in a Phase 2 European clinical trial of vipoglanstat, a non-hormonal and non-opioid drug candidate for endometriosis.
By June, the company reported that half of the planned 190 participants had been randomised, with top-line results expected in 2027.
Other research programmes are investigating different biological pathways and potential treatments.
This matters because the long-term innovation opportunity is not simply another way of suppressing symptoms.
It is understanding the biology of the disease well enough to create fundamentally different therapeutic options.
Endometriosis Has Been Historically Under-Researched
The disparity in research attention is also difficult to ignore.
A comparison previously raised in Parliament examined UK Research and Innovation’s awards database and found 35 endometriosis-related projects funded since 2003 compared with 1,758 relating to diabetes.
Those figures should not be interpreted as a direct comparison of total pounds invested because research databases, disease definitions and funding programmes are more complicated than simple keyword counts.
They nevertheless illustrate the historical difference in research activity.
More recent government figures suggest that investment is beginning to increase.
NIHR spending on active endometriosis research awards rose from approximately £494,000 in 2019/20 to £1.33 million in 2023/24. Across the five-year period, ten active NIHR research awards had a combined total award value of approximately £7.7 million.
UKRI separately had 18 relevant awards active between 2019/20 and 2023/24 with a combined award value of approximately £8.4 million.
In 2026, the government reiterated that the renewed Women’s Health Strategy would prioritise research into areas of unmet need including endometriosis.
The direction is encouraging, but the scale of unmet need remains substantial.
Britain Has an Interesting Innovation Advantage
The UK has several ingredients that could make it an important testbed for endometriosis innovation.
The NHS provides a national healthcare environment with large patient populations and potentially valuable longitudinal health information, subject to appropriate governance and privacy protections.
Britain also has strong universities, life-sciences companies, artificial-intelligence researchers and an increasingly active women’s-health innovation ecosystem.
The regulatory environment is changing too.
The Medicines and Healthcare products Regulatory Agency launched AI Airlock as the UK’s first regulatory sandbox specifically for artificial intelligence as a medical device.
The programme allows selected companies to work with regulators to investigate difficult questions surrounding AI medical technologies before they reach wider clinical use.
Following its first two phases, the government announced £3.6 million of funding in April 2026 to expand AI Airlock over the following three years.
Endometriosis technology is not automatically eligible or guaranteed entry, but the existence of this infrastructure matters.
A founder building an AI diagnostic product in women’s health is entering a regulatory environment that is actively trying to understand how these technologies can be evaluated safely.
The Opportunity Is Bigger Than Another Period Tracker
There is an important distinction between collecting more information from women and creating better healthcare from that information.
Women’s health technology has already demonstrated that people will record periods, symptoms, fertility information and intimate health experiences through digital products.
The next challenge is making those records clinically meaningful, interoperable and appropriately controlled.
| Opportunity | What Needs Solving |
|---|---|
| AI-assisted ultrasound | Help distribute specialist imaging expertise and identify suspicious patterns earlier. |
| Non-invasive diagnostics | Develop validated blood, biomarker or other tests that reduce reliance on invasive procedures. |
| Longitudinal symptom intelligence | Turn years of symptoms into clinically useful patterns rather than disconnected diary entries. |
| Clinical decision support | Help clinicians recognise when a patient’s history warrants investigation or specialist referral. |
| Patient-controlled health records | Allow people to carry their longitudinal endometriosis history between healthcare providers. |
| Research platforms | Enable appropriately consented longitudinal data to contribute to better understanding of the disease. |
| Non-hormonal therapeutics | Develop additional treatment options targeting disease biology and symptoms. |
| Clinical-trial matching | Connect eligible patients with relevant research and emerging therapies. |
The strongest companies may combine several of these capabilities.
A symptom diary alone has limited clinical value if the information never reaches the healthcare professional.
An AI model has limited value without sufficiently representative data.
A diagnostic test has limited value if it cannot pass clinical validation and regulation.
The opportunity sits in connecting these pieces.
The Patient Should Not Become the Product
There is also a lesson from the wider FemTech industry.
Solving endometriosis should not require women to surrender control over years of intimate information.
A longitudinal endometriosis record could contain menstrual history, sexual-health information, fertility information, pain experiences, medication, mental-health information and details about relationships and work.
That dataset could become scientifically and commercially valuable.
It is therefore essential that the next generation of women’s-health companies think about consent, privacy, portability and governance from the beginning rather than adding them after the product has been built.
The ambition should not simply be to extract more information from women.
It should be to use information to give women greater agency.
Commercialisation Is Not Starting From Zero
It would be incorrect to say that endometriosis has almost no patents.
A published patent-landscape analysis identified 144 patent applications relating to endometriosis diagnostics and therapeutics, including 26 focused on diagnostic applications and 116 relating to therapeutic approaches.
There are also active clinical trials and established pharmaceutical companies developing treatments.
The more interesting question is why innovation still feels so limited to patients despite that activity.
A patent is not a product.
A research paper is not a diagnostic service.
A successful laboratory experiment is not an NHS pathway.
The difficult journey from scientific discovery through validation, regulation, reimbursement and adoption is where much of the innovation challenge remains.
That is precisely where start-ups can matter.
The Bigger Picture
Endometriosis should not be interesting to technology founders simply because market analysts forecast a multibillion-dollar global treatment market.
The deeper opportunity is the size of the unresolved problem.
Millions of women live with the condition globally. Britain still has a diagnosis time measured in years rather than months. Researchers continue searching for better biomarkers and treatments. Specialist diagnostic expertise remains difficult to scale.
Behind those statistics are individual histories that can span much of a person’s adult life.
The future endometriosis technology stack could therefore look very different from today’s fragmented experience. Longitudinal health records could preserve the patient’s story. AI could help clinicians recognise patterns. Specialist imaging could become easier to scale. New diagnostics could reduce invasive investigation. New therapeutics could expand treatment choices.
None of those technologies will solve endometriosis alone.
But together they could attack one of the most frustrating characteristics of the condition: the enormous distance between experiencing something is wrong and finally understanding what it is.
That is where Britain’s endometriosis innovation opportunity becomes compelling.
The women waiting nine years for answers are not a niche market waiting to be discovered. They are patients waiting for healthcare innovation to catch up with a problem they have been describing for years.